Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) edged up 2% after the company shared encouraging interim results ...

Investing.com -- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock rose 2% following positive interim results from two Phase 2 clinical trials of its ARCT-810 mRNA therapeutic for ornithine ...

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

A faulty lab test report that triggers panic and emergency hospitalisation amounts to a deficiency in service, Delhi State ...

Yara South Asia's Managing Director discusses soil carbon deficiency, crop nutrition, and sustainability initiatives in India.

Over 30 million people in the U.S. are affected by one of more than 7,000 rare genetic disorders. (Image: Pixabay) KJ, an infant born in 2024, was diagnosed with a rate genetic disorder soon after ...

Urea may be the underrated MVP your skin needs. Here’s what to know about urea and the best brands that use it including Cerave, La Roche-Posay and more.

The global industry was valued at US$ 527.5 Mn in 2024 and is projected to exceed US$ 771.0 Mn by 2035, growing at a CAGR of 3.5% from 2025 to 2035The global urea cycle disorder (UCD) treatment market ...

Acute hyperammonemic encephalopathy secondary to ornithine transcarbamylase deficiency in a child: findings in diagnostic ... in Tl-weighted sequence and no gadolinium enhancement (Figure). A ...